CO5160248A1 - Metodo para tratar copd - Google Patents

Metodo para tratar copd

Info

Publication number
CO5160248A1
CO5160248A1 CO00014625A CO00014625A CO5160248A1 CO 5160248 A1 CO5160248 A1 CO 5160248A1 CO 00014625 A CO00014625 A CO 00014625A CO 00014625 A CO00014625 A CO 00014625A CO 5160248 A1 CO5160248 A1 CO 5160248A1
Authority
CO
Colombia
Prior art keywords
rolipram
pde4
inhibitor
pde
ratio
Prior art date
Application number
CO00014625A
Other languages
English (en)
Inventor
Siegfried B Christensen
Mary S Barnette
Theodore J Thorpy
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO5160248A1 publication Critical patent/CO5160248A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para la profilaxis o tratamiento de COPD en un ser humano, administrando un inhibidor específico de PDE 4 que inhibe preferentemente la forma catalítica de PDE 4 que une R-rolipram con una baja afinidad, cuyo método comprende administrar a un paciente que lo necesite una cantidad eficaz de un compuesto que tiene una relación de IC50 de aproximadamente 0,1 o más en relación con la IC50 para la forma de PDE 4 que une R-rolipram con una alta afinidad dividida por la IC50 para la forma catalítica que une R-rolipram con una baja afinidad, excluyendo cis-[4-ciano-4-(3-ciclopentiloxi-4-metoxifenil)ciclohexan-1-carboxilato].La fabricación de un medicamento para la profilaxis o para tratar COPD que comprende mezclar un inhibidor específico de PDE4 con un portador farmacéuticamente aceptable, en la que el inhibidor tiene una relación de IC50 de aproximadamente 0,1 o más en relación con la relación del valor de IC50 para competir con la unión de 1 nM, de [3H]R-rolipram a una forma de PDE4 que une rolipram con alta afinidad comparado con el valor de IC50 para inhibir la actividad catalítica de PDE4 de una forma que une rolipram con baja afinidad utilizando l3H]-cAMP 1 µM como substrato, excluyendo cis-[4-ciano-4-(3-ciclopentiloxi-4-metoxifenil)ciclohexan-1-carboxilato].
CO00014625A 1999-03-01 2000-03-01 Metodo para tratar copd CO5160248A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12231599P 1999-03-01 1999-03-01

Publications (1)

Publication Number Publication Date
CO5160248A1 true CO5160248A1 (es) 2002-05-30

Family

ID=22401990

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00014625A CO5160248A1 (es) 1999-03-01 2000-03-01 Metodo para tratar copd

Country Status (30)

Country Link
US (1) US6670394B1 (es)
EP (1) EP1156799A4 (es)
JP (1) JP2002538114A (es)
KR (1) KR20010102459A (es)
CN (1) CN1349403A (es)
AP (1) AP2001002248A0 (es)
AR (1) AR042369A1 (es)
AU (1) AU772583B2 (es)
BG (1) BG105953A (es)
BR (1) BR0008603A (es)
CA (1) CA2366036A1 (es)
CO (1) CO5160248A1 (es)
CZ (1) CZ20013149A3 (es)
DZ (1) DZ3019A1 (es)
EA (1) EA200100930A1 (es)
HK (1) HK1043935A1 (es)
HU (1) HUP0200288A3 (es)
ID (1) ID29888A (es)
IL (1) IL144992A0 (es)
MA (1) MA25522A1 (es)
NO (1) NO20014222L (es)
NZ (1) NZ513695A (es)
OA (1) OA11842A (es)
PE (1) PE20001505A1 (es)
PL (1) PL352816A1 (es)
SK (1) SK12372001A3 (es)
TR (1) TR200102514T2 (es)
UY (1) UY26040A1 (es)
WO (1) WO2000051598A1 (es)
ZA (1) ZA200107186B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
US20040005995A1 (en) * 2001-07-26 2004-01-08 Edelson Jeffrey D Method for reducing exacerbations associated with copd
AR029984A1 (es) * 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
ATE447555T1 (de) 2003-03-10 2009-11-15 Nycomed Gmbh Neues verfahren zur herstellung vonroflumilast
JPWO2004087148A1 (ja) * 2003-03-31 2006-06-29 協和醗酵工業株式会社 肺疾患の治療および／または予防剤
JPWO2005056009A1 (ja) * 2003-12-12 2007-07-05 協和醗酵工業株式会社 肺疾患治療剤
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
EP2258350B1 (en) 2005-03-16 2014-12-24 Takeda GmbH Taste masked dosage form containing roflumilast
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3251587B2 (ja) * 1992-04-02 2002-01-28 スミスクライン・ビーチャム・コーポレイション 炎症疾患の治療および腫瘍壊死因子の産生阻害に有用な化合物
HU225869B1 (en) * 1992-04-02 2007-11-28 Smithkline Beecham Corp Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
JPH08511805A (ja) 1993-06-18 1996-12-10 スミスクライン・ビーチャム・コーポレイション 化合物
US5728705A (en) * 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
PL314605A1 (en) * 1993-11-26 1996-09-16 Pfizer Isoxazolin compounds as anti-inflammatory agents
UY25338A1 (es) 1998-01-07 2001-08-27 Smithkline Beecham Corp Método para tratar copd

Also Published As

Publication number Publication date
AU772583B2 (en) 2004-04-29
WO2000051598A1 (en) 2000-09-08
TR200102514T2 (tr) 2002-04-22
HK1043935A1 (zh) 2002-10-04
EP1156799A4 (en) 2004-11-10
DZ3019A1 (fr) 2005-05-20
SK12372001A3 (sk) 2001-12-03
UY26040A1 (es) 2000-09-29
OA11842A (en) 2005-08-22
EP1156799A1 (en) 2001-11-28
IL144992A0 (en) 2002-06-30
NO20014222D0 (no) 2001-08-31
BG105953A (en) 2002-05-31
MA25522A1 (fr) 2002-10-01
ZA200107186B (en) 2002-08-30
HUP0200288A3 (en) 2003-08-28
HUP0200288A2 (hu) 2002-05-29
CZ20013149A3 (cs) 2002-04-17
CN1349403A (zh) 2002-05-15
US6670394B1 (en) 2003-12-30
AR042369A1 (es) 2005-06-22
CA2366036A1 (en) 2000-09-08
AU3386900A (en) 2000-09-21
PL352816A1 (en) 2003-09-08
BR0008603A (pt) 2001-12-26
AP2001002248A0 (en) 2001-09-30
NZ513695A (en) 2001-09-28
EA200100930A1 (ru) 2002-02-28
PE20001505A1 (es) 2001-02-08
ID29888A (id) 2001-10-18
JP2002538114A (ja) 2002-11-12
NO20014222L (no) 2001-10-29
KR20010102459A (ko) 2001-11-15

Similar Documents

Publication Publication Date Title
CO5160248A1 (es) Metodo para tratar copd
BR0315597A (pt) Processos de baixa dose para tratamento de distúrbios em que a atividade de tnf(alfa)é prejudicial
BRPI0413821A (pt) composto ou seus sais farmaceuticamente aceitáveis, composição farmacêutica, inibidor de gsk-3, e, agente para tratar ou prevenir um doença mediada por gsk-3
WO1997047296A3 (en) Compositions comprising vanadium compounds for use in the treatment of proliferative disorders and arthropathies
RS52781B (en) MEANS OF PREVENTION AND TREATMENT OF DISORDERS CONCERNING MODULATION OF RYR RECEPTORS
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
PT913156E (pt) Utilizacao de proteina c activada para tratar estados hipercoagulaveis associados com sepsia
CO5660275A2 (es) Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5
NO963493D0 (no) Middel for å fremme blodplatedannelse
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
BRPI0606393A2 (pt) prevenção de doenças trombóticas com compostos ativos de vitamina d ou similares do mesmo
ATE450265T1 (de) Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
WO2004038001A3 (en) Substituted tetracycline compounds for the treatment of malaria
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
PL370795A1 (en) Composition based on etyllinoleate and triethylcitrate for the treatment of seborrhea and acne
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
ID24870A (id) Penggunaan senyawa vanadium, garam dan kompleksnya yang dapat diterima secara fisiologi
BR9500436A (pt) Produtos uso de um g-csf uso de uma proteína tnf ligante processo para o tratamento e/ou prevenção do choque séptico
TW200509929A (en) Treatment of bipolar disorders and associated symptoms
BRPI0410654A (pt) composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto
WO2002098362A3 (en) Use of rank antagonists to treat cancer
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
Gertner Treatment with sildenafil for the healing of refractory skin ulcerations in the antiphospholipid syndrome
MX2009004607A (es) Metodo para administrar un compuesto antitumoral.